Amneal Pharmaceuticals, Inc.

Valuation Analysis

About the Company

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, in

Amneal Pharmaceuticals, Inc. Stock at a Glance

Amneal Pharmaceuticals, Inc. (AMRX) is currently trading at $16.20 with a market capitalization of $5.2B. The trailing P/E ratio stands at 43.78x, with a forward P/E of 14.42x. The 52-week range spans from $7.67 to $16.61; the current price is 2.5% below the yearly high. Year-over-year revenue growth stands at +3.9%. The net profit margin stands at 4.01%.

💰 Dividend

Amneal Pharmaceuticals, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

4 analysts rate Amneal Pharmaceuticals, Inc. (AMRX) on consensus: Strong Buy. The average price target is $17.25, implying +6.48% from the current price. Analyst price targets range from $16.00 to $19.00.

Amneal Pharmaceuticals, Inc.: The Investment Case in Detail

Amneal Pharmaceuticals, Inc. (AMRX) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Earnings growth of 384.6% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base.

The Bear Case

Revenue growth has slowed to just 3.9%, which is below nominal GDP — the business is no longer outgrowing the broader economy. With a net margin of just 4.01%, the business has little room to absorb cost shocks or pricing pressure — a single bad quarter can swing the company to a loss. The debt-to-equity ratio of 6750.84% is elevated, meaning the company relies heavily on creditors — refinancing terms will become more important than operational performance in the next economic downturn.

What to Watch Next

• The forward P/E of 14.42x is meaningfully below the trailing 43.78x — analysts expect earnings to step up; the next earnings release is the test.
• The share is trading at 95.4% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Risk Profile

The data points to market-like volatility, higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy Amneal Pharmaceuticals, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.